Lampe, George D. http://orcid.org/0000-0002-2873-2372
King, Rebeca T. http://orcid.org/0000-0001-5712-4539
Halpin-Healy, Tyler S.
Klompe, Sanne E.
Hogan, Marcus I.
Vo, Phuc Leo H. http://orcid.org/0000-0002-3719-7770
Tang, Stephen http://orcid.org/0000-0001-5492-9796
Chavez, Alejandro
Sternberg, Samuel H. http://orcid.org/0000-0001-8240-9114
Funding for this research was provided by:
Columbia University (T32GM008224-34, T32GM007367)
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (HG011855-01)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (DP2HG011650-01)
Article History
Received: 18 November 2021
Accepted: 13 March 2023
First Online: 29 March 2023
Competing interests
: Columbia University has filed a patent application related to this work. S.E.K., P.L.H.V., A.C. and S.H.S. are inventors on other patents and patent applications related to CRISPR–Cas systems and uses thereof. A.C. is a consultant for Vor Biopharma and an equity holder and scientific advisor for Cellgorithmics. S.H.S. is a co-founder of and scientific advisor to Dahlia Biosciences, a scientific advisor to Prime Medicine and CrisprBits and an equity holder in Dahlia Biosciences and CrisprBits. The remaining authors declare no competing interests.